Publicaciones en colaboración con investigadores/as de Hospital Universitario La Fe (78)

2024

  1. Are any specific respiratory viruses more severe than others in recipients of allogeneic stem cell transplantation? A focus on lower respiratory tract disease

    Bone Marrow Transplantation

  2. Outcome of Human Parainfluenza Virus infection in allogeneic stem cell transplantation recipients: possible impact of ribavirin therapy

    Infection

  3. Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis in HLA-Matched and Haploidentical Donor Transplantation for Patients with Hodgkin Lymphoma: A Comparative Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation

    Transplantation and Cellular Therapy, Vol. 30, Núm. 2, pp. 210.e1-210.e14

  4. Torque Teno Virus plasma DNA load: a novel prognostic biomarker in CAR-T therapy

    Bone Marrow Transplantation, Vol. 59, Núm. 1, pp. 93-100

  5. Upper and/or Lower Respiratory Tract Infection Caused by Human Metapneumovirus After Allogeneic Hematopoietic Stem Cell Transplantation

    Journal of Infectious Diseases, Vol. 229, Núm. 1, pp. 83-94

2023

  1. Cytomegalovirus DNAemia in haematological patients undergoing CD19-directed chimeric antigen receptor T-cell therapy: should it be systematically monitored?

    Clinical Microbiology and Infection

  2. Features of cytomegalovirus DNAemia and virus-specific T-cell responses in allogeneic hematopoietic stem-cell transplant recipients during prophylaxis with letermovir

    Transplant Infectious Disease, Vol. 25, Núm. 2

  3. One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients

    Blood Cancer Journal, Vol. 13, Núm. 1

  4. Quantifying the available capacity and resource needs for provision of CAR-T therapies in the National Health Service in Spain: a survey-based study

    BMJ open, Vol. 13, Núm. 7, pp. e071371

  5. Rationale for combined therapies in severe-to-critical COVID-19 patients

    Frontiers in Immunology, Vol. 14

  6. Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients

    Viruses, Vol. 15, Núm. 10

  7. Respiratory virus infections after allogeneic stem cell transplantation: Current understanding, knowledge gaps, and recent advances

    Transplant Infectious Disease, Vol. 25, Núm. S1

  8. SARS-CoV-2 Immunity in Hematopoietic Stem Cell Transplant and Cell Therapy Recipients: What Do We Know, and What Remains to Be Determined?

    Hemato, Vol. 4, Núm. 2, pp. 170-183

  9. SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination

    Bone Marrow Transplantation, Vol. 58, Núm. 5, pp. 567-580

2022

  1. Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients

    Annals of Hematology, Vol. 101, Núm. 9, pp. 2053-2067

  2. Post-Transplantation Cyclophosphamide After HLA Identical Compared to Haploidentical Donor Transplant in Acute Myeloid Leukemia: A Study on Behalf of GETH-TC

    Transplantation and Cellular Therapy, Vol. 28, Núm. 4, pp. 204.e1-204.e10

  3. Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia

    Bone Marrow Transplantation, Vol. 57, Núm. 9, pp. 1389-1398

  4. SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders

    Journal of hematology & oncology, Vol. 15, Núm. 1, pp. 54

  5. SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group

    American Journal of Hematology, Vol. 97, Núm. 1, pp. 30-42

2021

  1. Allogeneic Stem Cell Transplantation in Mature T Cell and Natural Killer/T Neoplasias: A Registry Study from Spanish GETH/GELTAMO Centers

    Transplantation and Cellular Therapy, Vol. 27, Núm. 6, pp. 493.e1-493.e8